CNS-fo­cused gene ther­a­py biotech forges man­u­fac­tur­ing deal for hear­ing loss drug

A grow­ing gene ther­a­py com­pa­ny is team­ing up with one of the largest gene ther­a­py man­u­fac­tur­ers to get its drug in­to pa­tients in clin­i­cal tri­als.

Myrtelle an­nounced on Mon­day that it inked a deal with Forge Bi­o­log­ics to make Myr-201, a gene ther­a­py in­di­cat­ed for mono­genic hear­ing loss. The tar­get pa­tient pop­u­la­tion, Myrtelle said, is peo­ple with a type of hear­ing loss called DFNB8, or au­to­so­mal re­ces­sive deaf­ness 8.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER